KOD vs. SAGE, CGEM, MRVI, TYRA, SIGA, RLAY, AKBA, MGTX, MNMD, and PGEN
Should you be buying Kodiak Sciences stock or one of its competitors? The main competitors of Kodiak Sciences include Sage Therapeutics (SAGE), Cullinan Therapeutics (CGEM), Maravai LifeSciences (MRVI), Tyra Biosciences (TYRA), SIGA Technologies (SIGA), Relay Therapeutics (RLAY), Akebia Therapeutics (AKBA), MeiraGTx (MGTX), Mind Medicine (MindMed) (MNMD), and Precigen (PGEN). These companies are all part of the "pharmaceutical products" industry.
Kodiak Sciences vs.
Kodiak Sciences (NASDAQ:KOD) and Sage Therapeutics (NASDAQ:SAGE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, community ranking, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.
Kodiak Sciences has higher earnings, but lower revenue than Sage Therapeutics. Kodiak Sciences is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks.
89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 99.2% of Sage Therapeutics shares are owned by institutional investors. 45.3% of Kodiak Sciences shares are owned by company insiders. Comparatively, 5.5% of Sage Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Kodiak Sciences has a net margin of 0.00% compared to Sage Therapeutics' net margin of -971.50%. Sage Therapeutics' return on equity of -68.18% beat Kodiak Sciences' return on equity.
Kodiak Sciences presently has a consensus target price of $9.00, suggesting a potential upside of 114.80%. Sage Therapeutics has a consensus target price of $8.81, suggesting a potential upside of 13.13%. Given Kodiak Sciences' higher possible upside, equities analysts plainly believe Kodiak Sciences is more favorable than Sage Therapeutics.
Sage Therapeutics received 614 more outperform votes than Kodiak Sciences when rated by MarketBeat users. Likewise, 65.12% of users gave Sage Therapeutics an outperform vote while only 27.14% of users gave Kodiak Sciences an outperform vote.
Kodiak Sciences has a beta of 2.4, indicating that its stock price is 140% more volatile than the S&P 500. Comparatively, Sage Therapeutics has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500.
In the previous week, Sage Therapeutics had 3 more articles in the media than Kodiak Sciences. MarketBeat recorded 13 mentions for Sage Therapeutics and 10 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.99 beat Sage Therapeutics' score of 0.48 indicating that Kodiak Sciences is being referred to more favorably in the media.
Summary
Kodiak Sciences beats Sage Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Kodiak Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for KOD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kodiak Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:KOD) was last updated on 4/25/2025 by MarketBeat.com Staff
Buy KOD Stock Free KOD Stock Alerts